Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser
MWN-AI** Summary
Kane Biotech Inc. (TSXV:KNE) achieved a significant milestone on February 17, 2026, by announcing the U.S. Food and Drug Administration (FDA) 510(k) clearance for its revyve® Antimicrobial Skin and Wound Cleanser. This innovative product aims to mechanically cleanse, moisten, debride, and remove foreign materials—including microorganisms—from various acute and chronic skin wounds such as pressure ulcers, diabetic foot ulcers, surgical wounds, and minor burns. The product's clearance paves the way for manufacturing technology transfer and enhanced sales activities later in the year, marking a crucial step in Kane’s wound care platform.
In addition to the FDA clearance, Kane Biotech has expanded its ISO 13485:2016 certification to include distribution in the Medical Device Single Audit Program (MDSAP), now applicable to wound cleansers. This move not only adds value to their existing certifications for antimicrobial wound dressings but also aligns with the FDA's newly implemented Quality Management System Regulation (QMSR), effective February 2026. The expanded certification enhances Kane’s capacity to navigate regulatory approvals internationally while bolstering its commitment to quality and compliance.
Lori Christofalos, Chief Quality Officer, emphasized that these advancements reflect Kane’s structured approach to enhancing its wound care portfolio, fostering trust among healthcare providers and patients. Kane Biotech is dedicated to revolutionizing wound care treatments aimed at combatting biofilms—major contributors to antibiotic resistance—promising improved healing outcomes.
Kane Biotech’s revyve® product line, which also includes Amicrobial Wound Gel and Gel Spray, has received both FDA 510(k) clearance and Health Canada approval, solidifying the Company’s position in the competitive wound care market. For more details, interested parties are encouraged to visit their website and subscribe to updates.
MWN-AI** Analysis
Kane Biotech Inc. (TSXV:KNE) has marked a significant achievement by securing FDA 510(k) clearance for its revyve® Antimicrobial Skin and Wound Cleanser, a move that positions the company optimally within the wound care market. This product is designed to improve healing in patients with a range of wounds, including chronic and acute lesions, which is crucial given the increasing prevalence of antibiotic resistance issues associated with wound care.
The FDA clearance not only validates Kane’s technological advancements but also opens the door for enhanced market penetration. Given the company's plans for manufacturing technology transfer and sales activities later in 2026, investors should monitor the execution of these initiatives closely. Actual revenue generation following commercialization will be a critical measure of Kane's operational success and could influence market valuation.
Moreover, the expansion of Kane's ISO 13485:2016 certification under the Medical Device Single Audit Program reflects the company’s commitment to high-quality manufacturing processes. This step aligns with the FDA’s recent regulatory updates and bolsters Kane's credibility among stakeholders. Investors could interpret this as a proactive measure that mitigates risks related to compliance, potentially resulting in improved partnerships within healthcare ecosystems.
While the achievements present a favorable outlook, potential investors should also consider the inherent risks associated with startups in the biotech sector. Kane's reliance on equity financing and the ambiguity surrounding revenue streams must be taken into account. It's imperative to assess the company’s ability to transition from product development to commercial viability effectively.
In conclusion, Kane Biotech's recent milestones present a positive investment case, contingent upon execution and market adoption of its products. Investors would be prudent to stay informed on the company's operational developments and industry trends as they shape the future of wound care solutions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WINNIPEG, Manitoba, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE) (“Kane Biotech”. “Kane” or the “Company”) today announces two regulatory milestones that strengthen the Company’s wound care platform and reinforce its commitment to high quality, evidence-based medical device development.
Kane has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its revyve® Antimicrobial Skin and Wound Cleanser, intended for the mechanical cleansing, moistening, debriding, and removal of foreign material — including microorganisms and debris — from a broad range of acute and chronic dermal lesions. These include Stage I–IV pressure ulcers, venous ulcers, leg ulcers, diabetic foot ulcers, postsurgical wounds, first and superficial second-degree burns, grafted and donor sites, as well as minor cuts, minor burns, and superficial abrasions. The cleanser is also intended for moistening absorbent wound dressings. With manufacturing technology transfer and scale-up of the cleanser planned for later in 2026 and sales activities shortly thereafter, this clearance represents an important validation of Kane’s expanded revyve product line. The technology platform is designed to address both wound bacteria and biofilms — two major contributors to delayed healing and antibiotic resistance.
In addition, Kane has expanded its ISO 13485:2016 certification under the Medical Device Single Audit Program (MDSAP) to include distribution while expanding to wound cleansers, building on its existing certifications for nonsterile antimicrobial wound dressings (revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray). This expansion is aligned with the FDA’s new Quality Management System Regulation (QMSR) which came into effect February 2026, harmonizing U.S. requirements with ISO 13485.
The expanded certification supports Kane’s ability to pursue regulatory approvals across multiple jurisdictions and demonstrates the Company’s continued investment in quality systems, compliance, and operational readiness.
“These achievements reflect Kane’s disciplined approach to advancing its wound care portfolio,” said Lori Christofalos, Chief Quality Officer. “ISO 13485 and MDSAP compliance strengthens trust among healthcare providers and patients, and ensures Kane is aligned with evolving regulatory expectations.”
About Kane Biotech Inc. (TSX-V:KNE)
Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve® addresses both biofilms and wound bacteria. revyve® Antimicrobial Wound Gel, revyve® Antimicrobial Wound Gel Spray and revyve® Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray are also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.
Join Kane’s Distribution List & Social Media:
To stay informed on the latest developments, sign up for the Company’s email distribution list HERE.
Follow Kane
Website: kanebiotech.com
LinkedIn: https://www.linkedin.com/company/kanebiotech/
Presentations: https://kanebiotech.com/publications-posters/
For more information:
| Dr. Robert Huizinga | Ray Dupuis |
| Interim CEO | Chief Financial Officer |
| Kane Biotech Inc. | Kane Biotech Inc. |
| rhuizinga@kanebiotech.com | rdupuis@kanebiotech.com |
| (780) 970-1100 | (204) 298-2200 |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ**
How does Kane Biotech Inc. (KNBIF) plan to utilize its recent FDA 510(k) clearance to enhance its market position in the wound care sector and drive revenue growth?
What specific benefits does the revyve® Antimicrobial Skin and Wound Cleanser offer compared to existing wound care products in terms of addressing biofilms and antibiotic resistance, as presented by Kane Biotech Inc. (KNBIF)?
With expanded ISO 13485:2016 certification under MDSAP, how does Kane Biotech Inc. (KNBIF) aim to ensure regulatory compliance and operational readiness in different jurisdictions within the next few years?
What are Kane Biotech Inc. (KNBIF)'s strategies for overcoming potential market acceptance challenges for its innovative wound care treatments, especially in light of its early-stage development status?
**MWN-AI FAQ is based on asking OpenAI questions about Kane Biotech Inc. (OTC: KNBIF).
NASDAQ: KNBIF
KNBIF Trading
0.0% G/L:
$0.026 Last:
35,000 Volume:
$0.026 Open:
